# A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

Source: https://onco.cc/trials/nct07231458/  
OnCo record `nct07231458` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ABX-001 run by Abalos Therapeutics GmbH, now recruiting.

## Summary

A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies is a phase 1 interventional study registered as NCT07231458 by Abalos Therapeutics GmbH, with 27 participants planned, started 2025-10-14. Conditions recorded: Advanced Solid Tumors. Interventions recorded: ABX-001 and Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07231458
- Phase: 1
- Setting: A Phase I/Ib Open-Label Study of ABX-001 Administered With and Without the Anti-PD-1 Immune Checkpoint Inhibitor Pembrolizumab in Participants With Advanced Solid Tumors Who Are Beyond Standard of Care
- Sponsor: Abalos Therapeutics GmbH
- Enrolled: 27

## Sources

- ClinicalTrials.gov NCT07231458: https://clinicaltrials.gov/study/NCT07231458

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [ABX-001](https://onco.cc/drugs/abx-001/)
- companies: [Abalos Therapeutics](https://onco.cc/companies/abalos-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07231458.json